A differentiated way to support neuropsychiatry assets across the lifecycle
Osmind actively supports sponsors ranging from top 5 pharma to clinical stage biotechs to neurotechnology companies.
Our projects have included retrospective RWD analyses, fit-for-purpose registries, prospective data capture, data-driven trials recruitment, market research, and commercial engagement (e.g. HCP education, patient identification).
Making an impact on psychiatry
"Osmind is doing important, much-needed work. I truly believe that we are at an inflection point in our ability to markedly improve outcomes for our patients – both from an improved understanding of novel therapeutics, and our ability to move towards precision medicine."
“Our collaboration with Osmind offers promise to broaden the scope of our impact on psychiatry and on the patients we serve.”
"We're at a critical juncture in neuropsychiatry. Leveraging real-world evidence can accelerate breakthrough treatment development. Osmind’s platform offers an extremely large source of longitudinal data. I'm excited to work with Osmind to develop more effective, personalized treatments for mental health conditions."
“Osmind’s approach to unlocking next-generation treatments by leveraging real-world evidence and their digital infrastructure has the potential to meaningfully impact our ability to bring new treatments to patients in dire need. They’ve made incredible progress already.”
Backed by industry leaders
Husseini Manji, MD
Former Global Head of Neuroscience, J&J
Rob Berman, MD
Co-founder and former Chief Medical Officer, Biohaven Pharmaceuticals
Jeff Leiden, MD, PhD
Executive Chairman, former President and CEO, Vertex Pharmaceuticals
Brent Saunders
CEO, Bausch & Lomb; Former CEO & Chairman, Allergan
Connecting the point-of-care with life sciences innovation
Our software is the
system of record
Our fully-integrated software platform includes an EHR, patient app, practice management system, clinician community, and advanced analytics system
Depth and quality of real-world data
High quality clinical and outcomes data at scale. Structured for research from the point of data generation, e.g. from our library of 50+ outcomes measures
Direct relationship
with clinics
Network of engaged, research-forward clinicians using our software and in our proprietary clinician community
Direct relationship
with patients
Network of engaged patients actively using our software
Accelerate your programs across the development lifecycle
Trusted by leading companies. Below are examples from recent
projects we have conducted.
Translational research
Example: We used RWD to develop novel subtypes of psychiatric conditions for more precise therapeutic targeting
Clinical development
Example: We used RWD to help design clinical trials and recruit patients for studies
Medical affairs, HEOR
Example: We assessed the real-world effectiveness and treatment patterns of novel psychiatric therapies and produced high-impact publications geared towards HCPs and payers
PV, safety studies, REMS
Example: We automated the REMS program and collected high quality, customized safety data on specific psychiatric treatments
Commercial
Example: We conducted market research studies to understand clinician perspectives, educated clinicians about new treatments, and helped them adjust their workflows accordingly (support across the funnel)
What we do
- RWE
- Retrospective analyses of EHR-derived RWD
- Fit-for-purpose registries
- Prospective data capture
- Data-driven trials recruitment
- Market research, physician and patient perspectives (qualitative, quantitative, linkage with RWD)
- Commercial, HCP engagement and education, patient identification
Featured news & research
Psychiatric Treatments that have FDA’s Breakthrough Therapy Status
MacMillan (2024). American Psychiatric Association Annual Meeting.
Osmind Announces Collaboration with the American Psychiatric Association to Advance Quality Psychiatric Care and Accelerate Research
A phase 2 trial with CLE-100 oral esketamine for patients with MDD and inadequate response to antidepressant during COVID-19 pandemic
Hagai et al. (2024). Oxford Ketamine Conference.
Osmind Announces 2024 Community Advisory Board: Leading Mental Health Clinicians
Considering New and Emerging Treatment Strategies for Depression: Beyond STAR*D and the Monoamines
McInnes and Marton (2024). Current Psychiatry Research and Reviews.
Embracing pragmatism for ketamine insurance coverage: Leveraging real-world evidence
McInnes, Marton, Qian (2024). Journal of Affective Disorders.
Osmind Announces 2023 Community Advisory Board: Leading Mental Health Clinicians
Machine Learning (ML) Algorithms for Prediction of Treatment Response to Ketamine Infusion Therapy (KIT)
Kane, Worley, McInnes (2023). American Society of Ketamine Physicians, Psychotherapists & Practitioners Annual Meeting.
Using a longitudinal model to predict outcomes to ketamine intravenous therapy for depression
Kane, Worley, McInnes (2023). American College of Neuropharmacology Annual Meeting.
Real world efficacy and safety of various accelerated deep TMS protocols for major depression
Roth, Hanlon, Pell et al. (2024). Psychiatric Research.
The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis
Hietamies, McInnes, Klise et al. (2023). Journal of Affective Disorders.
Prediction of treatment adherence to ketamine infusion therapy
Kane, Worley, Oldenkamp et al. (2023). Psychedelic Science.
CLEO: A Phase 2 Randomized Controlled Adjunctive Treatment Trial with CLE-100 Esketamine Tablet for Patients with Major Depressive Disorder and Inadequate Response to Antidepressants, During The COVID-19 Pandemic
Fava, Berkowitz, Mathew et al. (2023). American Society of Clinical Psychopharmacology Annual Meeting.
